Association study between brain-derived neurotrophic factor gene polymorphisms and methamphetamine abusers in Japan

Several lines of evidence suggest that genetic factors might contribute to drug abuse vulnerability. Recent genomic scans for association demonstrated that the brain‐derived neurotrophic factor (BDNF) gene was associated with drug abuse vulnerability. In this study, we analyzed association of two BD...

Full description

Saved in:
Bibliographic Details
Published in:American journal of medical genetics. Part B, Neuropsychiatric genetics Neuropsychiatric genetics, 2005-01, Vol.132B (1), p.70-73
Main Authors: Itoh, Kanako, Hashimoto, Kenji, Shimizu, Eiji, Sekine, Yoshimoto, Ozaki, Norio, Inada, Toshiya, Harano, Mutsuo, Iwata, Nakao, Komiyama, Tokutaro, Yamada, Mitsuhiko, Sora, Ichiro, Nakata, Kenji, Ujike, Hiroshi, Iyo, Masaomi
Format: Article
Language:English
Subjects:
Adult
Alleles
Amphetamine-Related Disorders - etiology
Amphetamine-Related Disorders - genetics
brain-derived neurotrophic factor
Brain-Derived Neurotrophic Factor - genetics
drug abuse
Female
Gene Frequency
Genotype
Humans
Japan
Male
methamphetamine
Methamphetamine - poisoning
Middle Aged
polymorphism
Polymorphism, Genetic
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Several lines of evidence suggest that genetic factors might contribute to drug abuse vulnerability. Recent genomic scans for association demonstrated that the brain‐derived neurotrophic factor (BDNF) gene was associated with drug abuse vulnerability. In this study, we analyzed association of two BDNF gene single nucleotide polymorphisms (SNPs), 132C > T (C270T named formerly) in the noncoding region of exon V and 196G > A (val66met) in the coding region of exon XIIIA, with methamphetamine (MAP) abuse in Japan. No significant differences were found in the frequency of the genotype or allele in these two SNPs between MAP abusers and controls (132C > T in exon V: genotype, P = 0.586, allele, P = 0.594; 196G > A (val66met) in exon XIIIA: genotype, P = 0.889, allele, P = 0.713). Furthermore, there was no difference between clinical parameters (e.g., prognosis psychosis, spontaneous relapse, or poly‐substance abuse) and the two SNPs of BDNF gene. These results suggest that the two SNPs (132C > T in exon V and 196G>A (val66met) in exon XIIIA) of the BDNF gene may not be associated with Japanese MAP abusers. This article contains supplementary material, which may be viewed at the American Journal of Medical Genetics website at http://www.interscience.wiley.com/jpages/0148‐7299:1/suppmat/index.html. © 2004 Wiley‐Liss, Inc.
ISSN:1552-4841
1552-485X
DOI:10.1002/ajmg.b.30097